Martin Marietta Materials Inc
Change company Symbol lookup
Select an option...
MLM Martin Marietta Materials Inc
VMC Vulcan Materials Co
SHLDQ Sears Holdings Corp
COTRP Corts Trust for JC Penney Debentures
M Macy's Inc
DDS Dillard's Inc
KSS Kohls Corp
MC Moelis & Co
MSFT Microsoft Corp
FRPH FRP Holdings Inc
Go

Materials : Construction Materials | Mid Cap Blend
Company profile

Martin Marietta Materials, Inc. is a natural resource-based building materials company. The Company supplies aggregates (crushed stone, sand, and gravel) through its network of approximately 310 quarries, mines and distribution yards in Canada and The Bahamas. In the southwestern and western United States, the Company also provides cement and downstream products and services, including ready-mixed concrete, asphalt, and paving services, in markets that are naturally vertically integrated. The Company has cement plants in Texas, and ready mixed concrete and asphalt operations in Texas, Colorado, and Wyoming. Asphalt operations and paving services are in Colorado. The Company conducts its Building Materials Business through two segments, East Group and West Group. The East Group provides aggregates products only. The West Group provides aggregates, cement, and downstream products. The Company’s Magnesia Specialties Business includes magnesia-based chemicals and dolomitic lime businesses.

Closing Price
$368.62
Day's Change
0.71 (0.19%)
Bid
--
Ask
--
B/A Size
--
Day's High
379.54
Day's Low
363.51
Volume
(Average)
Volume:
578,359

10-day average volume:
636,620
578,359

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Spectrum Pharmaceuticals, Inc of Class Action Lawsuit and Upcoming Deadline - SPPI

3:53 pm ET October 29, 2021 (Newsfile) Print

New York, New York--(Newsfile Corp. - October 29, 2021) -  Pomerantz LLP announces that a class action lawsuit has been filed against Spectrum Pharmaceuticals, Inc ("Spectrum" or the "Company") (NASDAQ: SPPI) and certain of its officers. The class action, filed in the United States District Court for the District of Nevada, and docketed under 21-cv-01612, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Spectrum securities between December 27, 2018 and August 5, 2021, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

If you are a shareholder who purchased or otherwise acquired Spectrum securities during the Class Period, you have until November 1, 2021 to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Robert S. Willoughby at newaction@pomlaw.com or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

[Click here for information about joining the class action]

Spectrum is a biopharmaceutical company that develops and commercializes oncology and hematology drug products. The Company's products under development include, among others, ROLONTIS (eflapegrastim), a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia.

In December 2018, Spectrum submitted a Biologics License Application ("BLA") to the U.S. Food and Drug Administration ("FDA") for ROLONTIS as a treatment for chemotherapy-induced neutropenia (the "ROLONTIS BLA").

The complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) the ROLONTIS manufacturing facility maintained deficient controls and/or procedures; (ii) the foregoing deficiencies decreased the likelihood that the FDA would approve the ROLONTIS BLA in its current form; (iii) Spectrum had therefore materially overstated the ROLONTIS BLA's approval prospects; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

On August 6, 2021, Spectrum announced receipt of a Complete Response Letter ("CRL") from the FDA regarding the ROLONTIS BLA. The CRL cited deficiencies related to manufacturing and indicated that a reinspection of the Company's manufacturing facility will be necessary.

On this news, Spectrum's stock price fell $0.70 per share, or 21.54%, to close at $2.55 per share on August 6, 2021.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

CONTACT:

Robert S. Willoughby

Pomerantz LLP

rswilloughby@pomlaw.com

888-476-6529 ext. 7980

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/101347

comtex tracking

COMTEX_396065012/2523/2021-10-29T15:53:21

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.